Use of Direct Oral Anticoagulants in Morbidly Obese Patients-Reference-Cited by-同舟云学术

Use of Direct Oral Anticoagulants in Morbidly Obese Patients

Published:2019-12-30 Issue:1 Volume:40 Page:72-83
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Kido Kazuhiko¹^ORCID,Lee James C.²,Hellwig Thaddaus³,Gulseth Michael P.⁴⁵

Affiliation:

1. Department of Clinical Pharmacy West Virginia University School of Pharmacy Morgantown West Virginia

2. University of Illinois at Chicago College of Pharmacy Chicago Illinois

3. Department of Pharmacy Practice South Dakota State University College of Pharmacy and Allied Health Professions Sioux Falls South Dakota

4. Anticoagulation Services Sanford USD Medical Center Sioux Falls South Dakota

5. Department of Internal Medicine University of South Dakota Sanford School of Medicine Sioux Falls South Dakota

Publisher

Wiley

Subject

Pharmacology (medical)

Link

Reference34 articles.

1. Bristol‐Myers Squibb and Pfizer.Eliquis (apixaban) package insert.Princeton NJ and New York;2019.

2. Boehringer Ingelheim Pharmaceuticals.Pradaxa (dabigatran) package insert.Ridgefield CT;2018.

3. Portola Pharmaceuticals.Bevyxxa (betrixaban) package insert.South San Francisco CA;2017.

4. Janssen Pharmaceuticals.Xarelto (rivaroxaban) package insert.Titusville NJ;2018.

5. Daiichi Sankyo Co.L. SAVAYSA (edoxaban) Package Insert.Tokyo Japan and Basking Ridge NJ;2017.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Oral Anticoagulants Beyond Warfarin;Annual Review of Pharmacology and Toxicology;2024-01-23